Creates provisions related to insurance coverage of annual kidney function screenings
Impact
If enacted, SB1737 would significantly affect the landscape of health insurance in Missouri by elevating the standards for preventive healthcare related to kidney health. By mandating coverage for kidney function screenings, the bill seeks to promote early detection of CKD, which is crucial for effective management and treatment of this condition. Supporters believe that this proactive approach could lead to better health outcomes and potentially reduce healthcare costs associated with advanced kidney disease treatments in the long run.
Summary
Senate Bill 1737 aims to amend chapter 376 of the Revised Statutes of Missouri by introducing a new section that mandates health carriers and health benefit plans to provide insurance coverage for annual kidney function screenings. These screenings are specifically intended to help identify patients who are at risk of developing chronic kidney disease (CKD). The bill requires coverage to encompass a range of diagnostic tests, including glomerular filtration rate testing, basic metabolic panel testing, and urine tests for albumin and creatinine levels, thus ensuring comprehensive assessment of kidney health for enrollees under these plans.
Contention
While the bill primarily aims to enhance preventive care, notable points of contention may arise from the implications it has on insurance premiums and the overall administrative burdens placed on health carriers. Critics may argue that requiring insurance providers to cover additional screening services could lead to increased costs for health plans, ultimately affecting premium rates for consumers. Additionally, some stakeholders might question the necessity of such mandates and whether they align with broader healthcare reform objectives. Therefore, while the bill promotes necessary health screenings, it may also ignite discussions about healthcare costs in a broader context.